Intravitreal Triamcinolone with Transpupillary Thermal Therapy (TTT) for Subfoveal Choroidal Neovascularization in Age Related Macular Degeneration

ISRCTN ISRCTN74123635
DOI https://doi.org/10.1186/ISRCTN74123635
Secondary identifying numbers N/A
Submission date
09/05/2005
Registration date
16/05/2005
Last edited
18/02/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Ricardo Agurto-Rivera
Scientific

Exequiel Fernández nº 920
Casa F
Ñuñoa
Santiago
Chile

Phone +56 8 5021968
Email ricardo_agurto@yahoo.com

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific title
Study objectivesTTT plus intravitreous triamcinolone are effective treatment for choroidal neovascularization and are better than TTT alone.
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedAge-Related Macular Degeneration (ARMD) not available for current therapies
InterventionComplete ophthalmologic examination, treatment with TTT alone compared with treatment with TTT plus intravitreous Triamcinolone. Ophthalmologic control to verify closure of CNV or re-treatment.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Triamcinolone
Primary outcome measurePreservation of visual acuity
Secondary outcome measuresClosure of CNV, OCT characteristics
Overall study start date01/02/2004
Completion date28/02/2006

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexNot Specified
Target number of participants200
Key inclusion criteriaPatients with severe ARMD (choroidal neovascularization [CNV]) that could not be treated with photodynamic therapy (PDT) because of bad prognosis or economical reasons.
Key exclusion criteria1. Any patient that has indication for PDT and has the economical means to get this therapy
2. Media opacity
3. Previous treatment for CNV
Date of first enrolment01/02/2004
Date of final enrolment28/02/2006

Locations

Countries of recruitment

  • Chile
  • Mexico

Study participating centre

Exequiel Fernández nº 920
Santiago
Chile

Sponsor information

Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)
Not defined

Vicente García Torres Nº 46
Barrio San Lucas
Del Coyoacán
Mexico City
04030
Mexico

Phone +52 10841400
Email retinamex@yahoo.com
ROR logo "ROR" https://ror.org/03sgfhr82

Funders

Funder type

Charity

Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 25/11/2005 Yes No